US6476205B1
Expired / Lapsed
US
⏱️ 0.0 years remaining
2′ Modified oligonucleotides
Assignee: Ionis Pharmaceuticals Inc
•
Filing: 1998-08-10
•
Granted: 2002-11-05
•
Expires: 2018-08-10
Abstract
Abstract Oligomers which have substituents on the 2' position are resistant to oligonucleases and furthermore can be derivatized to deliver reagents or drugs, to carry label, or to provide other properties.
Inventors
- 👤 Chris A. Buhr
- 👤 Mark Matteucci
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 21:40
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/06; C07H19/10; C07H19/16; C07H19/20; C07H21/00; C12N2310/00; C12N2310/30; C12N2310/32; C12N2310/321; C12N2310/322; C12N2310/35; C12N2310/351; C12N2310/3517; C12N2310/352; C12N2310/3527; C12N2310/353; C12N2310/3535
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
177 words
An oligonucleotide having the formula: or a salt thereof, wherein: each B independently is a protected or unprotected purine or pyrimidine base in the β-anomeric configuration; W 3 and W 4 are each independently H, PO 3 −2 , a protecting group, or an intermediate moiety in the formation of an internucleotide link which when reacted with the appropriate —OH results in Z; n is an integer of 1-200; each Z is independently is P(O)O, P(O)S or P(O)N(R) 2 provided at least one Z is not P(O)O; each R is independently H or alkyl (C 1-6 ); each A is OCH 3 , H, OH, O—Pr wherein Pr is a protecting group, or X—Y wherein: X is O; and Y is substituted or unsubstituted alkyl (C 2-20 ) or substituted or unsubstituted alkenyl (C 2-20 ), wherein the substituents are a halogen, OH, NH 2 , SH, —O—, —CH 2 CONH 2 , —CH 2 COOCH 2 CH 3 , or CH 2 CONHCH 2 NH 2 ; and at least one A is OCH 3 .
Claim 2
Dependent Claim
177 words
An oligonucleotide having the formula: or a salt thereof, wherein: each B independently is a protected or unprotected purine or pyrimidine base in the β-anomeric configuration; W 3 and W 4 are each independently H, PO 3 −2 , a protecting group, or an intermediate moiety in the formation of an internucleotide link which when reacted with the appropriate —OH results in Z; n is an integer of 1-200; each Z is independently is P(O)O, P(O)S or P(O)N(R) 2 provided at least one Z is not P(O)O; each R is independently H or alkyl (C 1-6 ); each A is OCH 3 , H, OH, O—Pr wherein Pr is a protecting group, or X—Y wherein: X is O; and Y is substituted or unsubstituted alkyl (C 2-20 ) or substituted or unsubstituted alkenyl (C 2-20 ), wherein the substituents are a halogen, OH, NH 2 , SH, —O—, —CH 2 CONH 2 , —CH 2 COOCH 2 CH 3 , or CH 2 CONHCH 2 NH 2 ; and at least one A is OCH 3 .
Claim 3
Dependent Claim
13 words
The oligonucleotide of claim 1 wherein W 3 and W 4 are H.
Claim 4
Dependent Claim
14 words
The oligonucleotide of claim 1 wherein at least one Z is P(O)N(R) 2 .
Claim 5
Dependent Claim
12 words
The oligonucleotide of claim 1 wherein at least one Z is P(O)S.
Claim 6
Dependent Claim
12 words
The oligonucleotide of claim 1 wherein at least one A is X—Y.
Claim 7
Dependent Claim
10 words
The oligonucleotide of claim 5 wherein Y is substituted alkyl.
References Cited (Backward Citations)
US4458066A
Cited
US4711955A
Cited
US4476301A
Cited
US4981957A
Cited
US4828979A
Cited
WO1986005518A1
Cited
US5013830A
Cited
EP0267996A1
Cited
EP0269574A2
Cited
US5264423A
Cited
US4924624A
Cited
WO1989005853A1
Cited
EP0339842A2
Cited
US5109126A
Cited
US5466786A
Cited
US5466786B1
Cited
US5792847A
Cited
EP0679657A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2005-11-04 | 2006-05-06 | 2006-11-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2009-11-04 | 2010-05-06 | 2010-11-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2013-11-04 | 2014-05-06 | 2014-11-05 | $7700.00 | Window Closed / Lapsed |